Authors (including presenting author) :
Chan WSS(1)(2), Tsang FH(1), Chu KP(2)
Affiliation :
(1) Pharmacy Department, United Christian Hospital, (2) Department of Pharmacology and Pharmacy, The University of Hong Kong
Introduction :
Diabetes mellitus is one of the extra-hepatic manifestations recognized among hepatitis C patients. It is discovered that sustained virologic response attainment could lower the diabetes incidence. Oral direct-acting antiviral medications, recommended by the World Health Organization owing to the promising virus eradication rate and good safety profile, might pose an effect on halting diabetes
Objectives :
To investigate the ability of direct-acting antiviral to revert type 2 diabetes mellitus risk in hepatitis C patients comparable to those who are uninfected.
Methodology :
In this study, the cumulative incidence of type 2 diabetes mellitus was measured in hepatitis C group with sustained virologic response using a direct-acting antiviral versus control group with no hepatitis C. 258 participants were recruited from the hepatitis C clinic in the United Christian Hospital for hepatitis C group where data of 258 patients in the control group with matched age and sex were drawn from Clinical Data Analysis and Reporting System.
Result & Outcome :
Over the one-year studying period, 3.88% and 0.78% of the patients were recorded with type 2 diabetes mellitus incidence in hepatitis C group and control group respectively. There was a statistically significant higher risk of type 2 diabetes development in the hepatitis C group (ORunadjusted 5.16, P = .019, 95% CI 1.12 – 23.79). Multivariate logistic regression identified hepatitis C infection as an independent variable related to type 2 diabetes (ORadjusted 6.51, 95% CI 1.31 – 32.2, P = .022).
